Tempus AI Launches Initiative to Build Largest Multimodal Whole-Genome Dataset for AI-Driven Healthcare
Tempus AI, Inc. (NASDAQ: TEM) has announced a new initiative to create a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. This effort aims to establish the first de-identified multimodal whole-genome sequencing (WGS) dataset specifically optimized for AI-driven research, built around disease populations and patient outcomes. Following the completion of this initial dataset, Tempus plans to expand the project with a long-term goal of reaching one million genomes. Unlike existing population-scale genome programs that primarily draw from general populations, Tempus's dataset will integrate genomic data with longitudinal disease and treatment outcomes. The company has already developed one of the largest multimodal real-world oncology databases, which has been used to inform drug development decisions. This new WGS dataset will be incorporated into Tempus’ existing de-identified multimodal data environment, allowing researchers to acces...
